Phase i study of neratinib in combination with temsirolimus in patients with human epidermal growth factor receptor 2-dependent and other solid tumors

Journal of Clinical Oncology

Volumn 32, Issue 2, 2014, Pages 68-75

  Gandhi, Leena ^a   Bahleda, Rastislav ^f   Tolaney, Sara M ^a   Kwak, Eunice L ^b   Cleary, James M ^a   Pandya, Shuchi S ^c   Hollebecque, Antoine ^f   Abbas, Richat ^g   Ananthakrishnan, Revathi ^e   Berkenblit, Anna ^d   Krygowski, Mizue ^d   Liang, Yali ^g   Turnbull, Kathleen W ^e   Shapiro, Geoffrey I ^a   Soria, Jean Charles ^f  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^d AVEO Pharmaceuticals   (United States)

^e SYNEOS HEALTH   (United States)

^f Insitut Gussav Roussy   (France)

^g PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; N (4 (3 CHLORO 4 (2 PYRIDINYLMETHOXY)ANILINO) 3 CYANO 7 ETHOXY 6 QUINOLYL) 4 (DIMETHYLAMINO) 2 BUTENAMIDE; N-(4-(3-CHLORO-4-(2-PYRIDINYLMETHOXY)ANILINO)-3-CYANO-7-ETHOXY-6-QUINOLYL)-4-(DIMETHYLAMINO)-2-BUTENAMIDE; PHOSPHATIDYLINOSITOL 3 KINASE; QUINOLINE DERIVATIVE; RAPAMYCIN; TARGET OF RAPAMYCIN KINASE; TEMSIROLIMUS;

AGED; ANEMIA; AREA UNDER THE CURVE; ARTICLE; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; DIARRHEA; DOSE RESPONSE; DRUG EFFECT; FEMALE; GENE AMPLIFICATION; GENETICS; HUMAN; LUNG TUMOR; MALE; METABOLISM; MIDDLE AGED; MUTATION; NAUSEA; NEOPLASM; PHASE 1 CLINICAL TRIAL; SIGNAL TRANSDUCTION; STOMATITIS; TREATMENT OUTCOME;

AGED; ANEMIA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; BREAST NEOPLASMS; DIARRHEA; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENE AMPLIFICATION; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NAUSEA; NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; QUINOLINES; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION; SIROLIMUS; STOMATITIS; TOR SERINE-THREONINE KINASES; TREATMENT OUTCOME;

EID: 84894807977     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.47.2787     Document Type: Article

References (37)

1. Wang SE, Narasanna A, Perez-Torres M, et al: HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors. Cancer Cell 10:25-38, 2006
2. Minami Y, Shimamura T, Shah K, et al: The major lung cancer-derived mutants of ERBB2 are oncogenic and are associated with sensitivity to the irreversible EGFR/ERBB2 inhibitor HKI-272. Oncogene 26:5023-5027, 2007 (Pubitemid 47172642)
3. Shimamura T, Ji H, Minami Y, et al: Non-small-cell lung cancer and Ba/F3 transformed cells harboring the ERBB2 G776insV-G/C mutation are sensitive to the dual-specific epidermal growth factor receptor and ERBB2 inhibitor HKI-272. Cancer Res 66:6487-6491, 2006 (Pubitemid 44085601)
4. Di Fiore PP, Pierce JH, Kraus MH, et al: erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. Science 237:178-182, 1987 (Pubitemid 17095921)
5. Hudziak RM, Schlessinger J, Ullrich A: Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells. Proc Natl Acad Sci U S A 84:7159-7163, 1987
6. Cobleigh MA, Vogel CL, Tripathy D, et al: Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17:2639-2648, 1999 (Pubitemid 29415219)
7. Seidman AD, Fornier MN, Esteva FJ, et al: Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol 19:2587-2595, 2001 (Pubitemid 32441364)
8. Baselga J, Cortés J, Kim SB, et al: Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 366:109-119, 2012
9. Garrett JT, Arteaga CL: Resistance to HER2-directed antibodies and tyrosine kinase inhibitors: Mechanisms and clinical implications. Cancer Biol Ther 11:793-800, 2011
10. Arteaga CL, Sliwkowski MX, Osborne CK, et al: Treatment of HER2-positive breast cancer: Current status and future perspectives. Nat Rev Clin Oncol 9:16-32, 2012
11. Gallardo A, Lerma E, Escuin D, et al: Increased signalling of EGFR and IGF1R, and deregulation of PTEN/PI3K/Akt pathway are related with trastuzumab resistance in HER2 breast carcinomas. Br J Cancer 106:1367-1373, 2012
12. Miller TW, Rexer BN, Garrett JT, et al: Mutations in the phosphatidylinositol 3-kinase pathway: Role in tumor progression and therapeutic implications in breast cancer. Breast Cancer Res 13:224, 2011
13. Cancer Genome Atlas Network: Comprehensive molecular portraits of human breast tumors. Nature 490:61-70, 2012
14. Stephens P, Hunter C, Bignell G, et al: Lung cancer: Intragenic ERBB2 kinase mutations in tumours. Nature 431:525-526, 2004
15. Shigematsu H, Takahashi T, Nomura M, et al: Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. Cancer Res 65:1642-1646, 2005 (Pubitemid 40478587)
16. Mounawar M, Mukeria A, Le Calvez F, et al: Patterns of EGFR, HER2, TP53, and KRAS mutations of p14arf expression in non-small cell lung cancers in relation to smoking history. Cancer Res 67:5667-5672, 2007 (Pubitemid 46984998)
17. Junker K, Stachetzki U, Rademacher D, et al: HER2/neu expression and amplification in non-small cell lung cancer prior to and after neoadjuvant therapy. Lung Cancer 48:59-67, 2005 (Pubitemid 40381000)
18. Heinmöller P, Gross C, Beyser K, et al: HER2 status in non-small cell lung cancer: Results from patient screening for enrollment to a phase II study of Herceptin. Clin Cancer Res 9:5238-5243, 2003
19. Pellegrini C, Falleni M, Marchetti A, et al: HER-2/Neu alterations in non-small cell lung cancer: A comprehensive evaluation by real time reverse transcription-PCR, fluorescence in situ hybridization, and immunohistochemistry. Clin Cancer Res 9:3645-3652, 2003 (Pubitemid 37169230)
20. Burstein HJ, Sun Y, Dirix LY, et al: Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer. J Clin Oncol 28:1301-1307, 2010
21. Perera SA, Li D, Shimamura T, et al: HER2YVMA drives rapid development of adenosquamous lung tumors in mice that are sensitive to BIBW2992 and rapamycin combination therapy. Proc Natl Acad Sci U S A 106:474-479, 2009
22. García-García C, Ibrahim YH, Serra V, et al: Dual mTORC1/2 and HER2 blockade results in antitumor activity in preclinical models of breast cancer resistant to anti-HER2 therapy. Clin Cancer Res 18:2603-2612, 2012
23. Chandarlapaty S, Sawai A, Scaltriti M, et al: AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer Cell 19:58-71, 2011
24. Rodrik-Outmezguine VS, Chandarlapaty S, Pagano NC, et al: MTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling. Cancer Discov 1:248-259, 2011
25. Ivanova A, Wang K: A non-parametric approach to the design and analysis of two-dimensional dose-finding trials. Stat Med 23:1861-1870, 2004 (Pubitemid 38787088)
26. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
27. Wong KK, Fracasso PM, Bukowski RM, et al: A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors. Clin Cancer Res 15:2552-2558, 2009
28. Lunardi G, Armirotti A, Nicodemo M, et al: Comparison of temsirolimus pharmacokinetics in patients with renal cell carcinoma not receiving dialysis and those receiving hemodialysis: A case series. Clin Ther 31:1812-1819, 2009
29. Raymond E, Alexandre J, Faivre S, et al: Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J Clin Oncol 22:2336-2347, 2004 (Pubitemid 41115390)
30. Sequist LV, Besse B, Lynch TJ, et al: Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: Results of a phase II trial in patients with advanced non-small-cell lung cancer. J Clin Oncol 28:3076-3083, 2010
31. Atkins MB, Hidalgo M, Stadler WM, et al: Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 22:909-918, 2004 (Pubitemid 41103603)
32. Gandhi L, Butaney M, Shaw A, et al: HER2 mutations in non-small cell lung cancer: Preliminary efficacy of targeted therapy with neratinib + torisel on a phase I trial. Presented at the World Conference on Lung Cancer, Amsterdam, the Netherlands, July 3-7, 2011
33. Pan CC, Chen PC, Wang LS, et al: Expression of apoptosis-related markers and HER-2/neu in thymic epithelial tumours. Histopathology 43:165-172, 2003 (Pubitemid 36963161)
34. Grivas PD, Day M, Hussain M: Urothelial carcinomas: A focus on human epidermal receptors signaling. Am J Transl Res 3:362-373, 2011
35. Lammers RJ, Witjes JA: Discussion on the influence of HER2 status on the clinical outcome of bladder cancer continues. Expert Rev Anticancer Ther 11:853-858, 2011
36. Li D, Shimamura T, Ji H, et al: Bronchial and peripheral murine lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272 and rapamycin combination therapy. Cancer Cell 12:81-93, 2007 (Pubitemid 47001787)
37. Gajria D, King T, Pannu H, et al: Combined Inhibition of mTORC1 with temsirolimus and HER2 with neratinib: A phase I/II study in patients with metastatic HER2-amplified or triple-negative breast cancer. Presented at the San Antonio Breast Cancer Symposium, San Antonio, TX, December 4-8, 2012